title: Inhibition of proliferation in colon cancer cell lines and harmful enzyme activity of colon bacteria by Bifidobacterium adolescentis SPM0212.
abstract: In this study, we assessed the anticancer activity and bacterial enzyme inhibition of Bifidobacterium adolescentis SPM0212. B. adolescentis SPM0212 inhibited the proliferation of three human colon cancer cell lines: HT-29, SW 480, and Caco-2. SPM0212 also dose-dependently inhibited TNF-á production and changes in cellular morphology. B. adolescentis SPM0212 inhibited harmful fecal enzymes, including â-glucuronidase, â-glucosidase, tryptophanase, and urease. Thus, B. adolescentis SPM0212 exerts an anticancer effect and inhibits harmful fecal enzymes.
authors.affiliation: Department of Pharmacy, Sahmyook University, Seoul, Korea.
authors.forename: Yuna
authors.initials: Y
authors.lastname: Kim
authors.forename: Dokyung
authors.initials: D
authors.lastname: Lee
authors.forename: Donghyun
authors.initials: D
authors.lastname: Kim
authors.forename: Jooyong
authors.initials: J
authors.lastname: Cho
authors.forename: Jaewook
authors.initials: J
authors.lastname: Yang
authors.forename: Myungjun
authors.initials: M
authors.lastname: Chung
authors.forename: Kyungjae
authors.initials: K
authors.lastname: Kim
authors.forename: Namjoo
authors.initials: N
authors.lastname: Ha
mesh_terms: D000328:Adult; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D044466:Asian People; D001426:Bacterial Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D001483:Base Sequence; D001644:Bifidobacterium / Q000145:classification / Q000235:genetics; D018938:Caco-2 Cells; D049109:Cell Proliferation / Q000187:drug effects*; D048430:Cell Shape / Q000187:drug effects; D044602:Cellulases / Q000037:antagonists & inhibitors / Q000378:metabolism; D003106:Colon / Q000382:microbiology*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D005243:Feces / Q000382:microbiology; D005966:Glucuronidase / Q000037:antagonists & inhibitors / Q000378:metabolism; D019073:HT29 Cells; D006801:Humans; D007723:Korea; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D008969:Molecular Sequence Data; D019936:Probiotics / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D014368:Tryptophanase / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014510:Urease / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D001426:Bacterial Proteins; D004791:Enzyme Inhibitors; D014409:Tumor Necrosis Factor-alpha; D044602:Cellulases; D005966:Glucuronidase; D014510:Urease; D014368:Tryptophanase